Key result
Elevated plasma IL-6 levels were significantly associated with depressive symptoms in individuals with COPD, independent of airflow limitation and comorbidities (OR 1.52; 95% CI 1.13-2.04).
Why the study?
Depression is a prevalent COPD comorbidity associated with inflammation, but this association had not been validated in a large COPD cohort.
Is systemic inflammation (plasma IL-6) associated with depressive symptoms in individuals with COPD?
Cohort (n=965)
Yes
Is systemic inflammation (plasma IL-6) associated with depressive symptoms in individuals with COPD?
Elevated plasma IL-6 levels are independently associated with depressive symptoms in patients with COPD, suggesting systemic inflammation may play a role in COPD-related depression.
Rationale: Depression is a prevalent comorbidity of chronic obstructive pulmonary disease (COPD) that, along with COPD, has been associated with inflammation. An association between inflammation and depression in COPD has not been validated in a large COPD cohort. Methods: Individuals from the University of Pittsburgh SCCOR cohort and the COPDGene cohort with tobacco use history and airway obstruction (FEV 1 /FVC < 0.7) were evaluated using the Beck Depression Inventory II (BDI-II) and the Hospital Anxiety and Depression Scale (HADS), respectively. Participants completed symptom-related questionnaires and plasma IL-6 measurements. T -test, Fisher’s Exact tests and logistic regression were used for statistical analysis. Results: The SCCOR cohort included 220 obstructed participants: 44% female and 21.4% with elevated depressive symptoms. GOLD staging distribution was predominantly stage I and II. The COPDGene cohort included 745 obstructed participants: 44% female and 13.0% with elevated depressive symptoms. GOLD distribution was predominantly stage II and III. In the SCCOR cohort, correlation between IL-6 and depressive symptoms trended toward significance (p= 0.08). Multivariable modeling adjusted for FEV 1 , age, gender and medical comorbidities showed a significant association (OR = 1.70, 95% CI = 1.08– 2.69). IL-6 was significantly associated with elevated depressive symptoms in COPDGene in both univariate (p=0.001) and multivariable modeling (OR = 1.52, 95% CI =1.13– 2.04). Conclusion: Elevated plasma IL-6 levels are associated with depressive symptoms in individuals with COPD independent of airflow limitation and comorbid risk factors for depression. Our results suggest that systemic inflammation may play a significant and possibly bidirectional role in depression associated with COPD.
No takes yet. Share an insight, caveat, or question.
Strollo et al. (2021) conducted a cohort in Chronic obstructive pulmonary disease (COPD) (n=965). Elevated plasma IL-6 levels was evaluated on Elevated depressive symptoms (OR 1.52, 95% CI 1.13-2.04, p=0.001). Elevated plasma IL-6 levels were significantly associated with depressive symptoms in individuals with COPD, independent of airflow limitation and comorbidities (OR 1.52; 95% CI 1.13-2.04).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: